Drug intelligence / Profile preview

GI-6300

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**GI-6300** is a Tarmogen product series developed by GlobeImmune, consisting of yeast-based immunotherapy platforms designed to target cancers expressing specific antigens. The lead candidate **GI-6301** targets the brachyury protein, which is implicated in metastatic progression of tumors such as chordoma. Tarmogens stimulate T-cell immune responses against tumor-associated antigens, aiming to induce antitumor immunity. GlobeImmune licensed the GI-6300 series exclusively to Celgene (now Bristol Myers Squibb) in 2013.

Targets

T (Brachyury transcription factor)

Beyond the preview

Go deeper on GI-6300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GI-6300.

Explore the full profile